Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Prudential Financial Inc. lessened its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 25.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 144,850 shares of the company’s stock after selling 49,500 shares during the period. Prudential Financial Inc. owned 0.21% of Nkarta worth $361,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of Nkarta by 97.1% in the third quarter. FMR LLC now owns 133,149 shares of the company’s stock valued at $602,000 after purchasing an additional 65,600 shares during the last quarter. State Street Corp grew its stake in Nkarta by 1.4% in the 3rd quarter. State Street Corp now owns 1,098,062 shares of the company’s stock valued at $4,963,000 after buying an additional 15,569 shares during the last quarter. Wellington Management Group LLP raised its holdings in Nkarta by 24.8% in the 3rd quarter. Wellington Management Group LLP now owns 216,341 shares of the company’s stock valued at $978,000 after acquiring an additional 43,035 shares during the period. XTX Topco Ltd acquired a new stake in Nkarta during the third quarter worth approximately $223,000. Finally, Barclays PLC boosted its holdings in shares of Nkarta by 161.4% during the third quarter. Barclays PLC now owns 232,566 shares of the company’s stock worth $1,051,000 after acquiring an additional 143,608 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.70% of the company’s stock.

Nkarta Stock Down 2.5 %

NKTX stock opened at $1.53 on Friday. The company has a market cap of $108.57 million, a PE ratio of -0.81 and a beta of 0.83. Nkarta, Inc. has a 52 week low of $1.31 and a 52 week high of $9.11. The business has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $2.57.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, analysts anticipate that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

NKTX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Nkarta in a report on Wednesday. Finally, Stifel Nicolaus reduced their target price on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.86.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.